Longer Predialysis ACEi/ARB Utilization Is Associated With Reduced Postdialysis Mortality.
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB)
Dialysis
End-stage kidney disease (ESKD)
Mortality
Veterans
Journal
The American journal of medicine
ISSN: 1555-7162
Titre abrégé: Am J Med
Pays: United States
ID NLM: 0267200
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
18
12
2019
revised:
07
03
2020
accepted:
14
03
2020
pubmed:
25
4
2020
medline:
24
11
2020
entrez:
25
4
2020
Statut:
ppublish
Résumé
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) improve predialysis outcomes; however, ACEi/ARB are underused in patients transitioning to dialysis. We examined the association of different patterns of predialysis ACEi/ARB use with postdialysis survival and whether potentially modifiable adverse events are associated with lower predialysis ACEi/ARB use. This was a historic cohort study of 34,676 US veterans with, and 10,690 without, ACEi/ARB exposure in the 3-year predialysis period who subsequently transitioned to dialysis between 2007 and 2014. Associations of different patterns of predialysis ACEi/ARB use with postdialysis all-cause mortality and with predialysis acute kidney injury and hyperkalemia events were examined using multivariable adjusted regression analyses. The mean age of the cohort was 70 years, 98% were males and 27% were African Americans. Compared to ACEi/ARB nonuse, continuous ACEi/ARB use was associated with lower postdialysis all-cause mortality (adjusted hazard ratio [aHR]; 95% confidence interval [95% CI] 0.87; 0.83-0.92). In analyses modeling the duration of predialysis ACEi/ARB use, ACEi/ARB use of 50%-74% and ≥75% were associated with lower mortality compared to nonuse (adjusted hazard ratio, 95% confidence interval 0.96, 0.92-0.99 and 0.91; 0.88-0.94, respectively), whereas no increase in postdialysis survival was observed with shorter predialysis ACEi/ARB use. Predialysis acute kidney injury was associated with shorter duration (<50%) of ACEi/ARB use and hyperkalemia was associated with interrupted and ACEi/ARB use of <75%. Longer predialysis ACEi/ARB exposure was associated with lower postdialysis mortality. Prospective studies are needed to evaluate the benefits of strategies enabling uninterrupted predialysis ACEi/ARB use.
Sections du résumé
BACKGROUND
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) improve predialysis outcomes; however, ACEi/ARB are underused in patients transitioning to dialysis. We examined the association of different patterns of predialysis ACEi/ARB use with postdialysis survival and whether potentially modifiable adverse events are associated with lower predialysis ACEi/ARB use.
METHODS
This was a historic cohort study of 34,676 US veterans with, and 10,690 without, ACEi/ARB exposure in the 3-year predialysis period who subsequently transitioned to dialysis between 2007 and 2014. Associations of different patterns of predialysis ACEi/ARB use with postdialysis all-cause mortality and with predialysis acute kidney injury and hyperkalemia events were examined using multivariable adjusted regression analyses.
RESULTS
The mean age of the cohort was 70 years, 98% were males and 27% were African Americans. Compared to ACEi/ARB nonuse, continuous ACEi/ARB use was associated with lower postdialysis all-cause mortality (adjusted hazard ratio [aHR]; 95% confidence interval [95% CI] 0.87; 0.83-0.92). In analyses modeling the duration of predialysis ACEi/ARB use, ACEi/ARB use of 50%-74% and ≥75% were associated with lower mortality compared to nonuse (adjusted hazard ratio, 95% confidence interval 0.96, 0.92-0.99 and 0.91; 0.88-0.94, respectively), whereas no increase in postdialysis survival was observed with shorter predialysis ACEi/ARB use. Predialysis acute kidney injury was associated with shorter duration (<50%) of ACEi/ARB use and hyperkalemia was associated with interrupted and ACEi/ARB use of <75%.
CONCLUSIONS
Longer predialysis ACEi/ARB exposure was associated with lower postdialysis mortality. Prospective studies are needed to evaluate the benefits of strategies enabling uninterrupted predialysis ACEi/ARB use.
Identifiants
pubmed: 32330490
pii: S0002-9343(20)30343-0
doi: 10.1016/j.amjmed.2020.03.037
pmc: PMC7483641
mid: NIHMS1586209
pii:
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1065-1073.e3Subventions
Organisme : HSRD VA
ID : SDR 02-237
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK102163
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
Circulation. 2009 Oct 20;120(16):1577-84
pubmed: 19805651
Am Heart J. 2007 Jun;153(6):1064-73
pubmed: 17540211
Nephron Clin Pract. 2012;120(1):c8-16
pubmed: 22156587
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Nephrol Dial Transplant. 2014 Mar;29(3):672-81
pubmed: 24398888
Kidney Int. 2006 Oct;70(7):1318-24
pubmed: 16871247
BMJ Open. 2016 Dec 21;6(12):e012690
pubmed: 28003286
Am J Kidney Dis. 2016 May;67(5):728-41
pubmed: 26597926
J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8
pubmed: 21070920
JAMA Intern Med. 2018 Dec 1;178(12):1681-1690
pubmed: 30422153
Am J Kidney Dis. 2008 Sep;52(3):501-6
pubmed: 18653268
Nephrol Dial Transplant. 2010 Dec;25(12):3977-82
pubmed: 19820248
BMC Nephrol. 2017 Nov 29;18(1):342
pubmed: 29187194
Circulation. 2004 Dec 14;110(24):3667-73
pubmed: 15569840
Nephrol Dial Transplant. 2017 Aug 1;32(8):1330-1337
pubmed: 27242372
Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1401-12
pubmed: 27354656
Popul Health Metr. 2006 Apr 10;4:2
pubmed: 16606453
Ann Intern Med. 2001 Apr 17;134(8):629-36
pubmed: 11304102
Cardiology. 2005;104(1):24-30
pubmed: 15942180
JAMA Netw Open. 2018 Oct 5;1(6):e182311
pubmed: 30646217
Nephrol Dial Transplant. 2019 Nov 1;34(11):1894-1901
pubmed: 29986054
Kidney Int. 2005 Aug;68(2):826-32
pubmed: 16014062
J Am Coll Cardiol. 2014 Feb 25;63(7):650-658
pubmed: 24269363
J Am Soc Nephrol. 2007 Oct;18(10):2766-72
pubmed: 17804673
Nephron. 2016;133(3):147-58
pubmed: 27336470
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Am J Kidney Dis. 2017 Mar;69(3 Suppl 1):A7-A8
pubmed: 28236831
Kidney Int. 2000 Nov;58(5):2084-92
pubmed: 11044229
Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48
pubmed: 20150448
Nephrol Dial Transplant. 2016 Feb;31(2):255-61
pubmed: 26429974
Nephrol Dial Transplant. 2006 Sep;21(9):2507-12
pubmed: 16766543
JAMA Intern Med. 2014 Mar;174(3):347-54
pubmed: 24343093
Rev Endocr Metab Disord. 2017 Mar;18(1):41-47
pubmed: 27600582
Am J Nephrol. 2015;42(5):361-8
pubmed: 26606453
PLoS One. 2017 Jan 25;12(1):e0170874
pubmed: 28122064
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Circulation. 2004 Mar 2;109(8):1004-9
pubmed: 14769700
Am J Nephrol. 2015;41(6):456-63
pubmed: 26228532
Am J Kidney Dis. 2018 Dec;72(6):873-884
pubmed: 30201547
J Card Fail. 2006 Sep;12(7):499-506
pubmed: 16952782
Am J Kidney Dis. 2017 Aug;70(2):207-217
pubmed: 28291617